Myriad Genetics (MYGN) Operating Expenses (2009 - 2026)

Myriad Genetics (MYGN) has 18 years of Operating Expenses data on file, last reported at $168.3 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $168.3 million, up 3.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $968.9 million (up 37.14% YoY), and the FY2025 annual result was $963.8 million, up 35.96% from the prior year.
• Operating Expenses rose to $168.3 million in Q1 2026 per MYGN's latest filing, from $152.5 million in the prior quarter.
• Over five years, Operating Expenses peaked at $481.0 million in Q2 2025 and troughed at -$8.2 million in Q4 2023.
• A 5-year average of $190.1 million and a median of $183.6 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2023 and 2024: Operating Expenses sank 129.29% in 2023, then soared 2415.85% in 2024.
• A 5-year view of Operating Expenses shows it stood at $28.0 million in 2022, then sank by 129.29% to -$8.2 million in 2023, then soared by 2415.85% to $189.9 million in 2024, then decreased by 19.69% to $152.5 million in 2025, then climbed by 10.36% to $168.3 million in 2026.
• Business Quant data shows MYGN's Operating Expenses at $168.3 million in Q1 2026, $152.5 million in Q4 2025, and $167.1 million in Q3 2025.